Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Synthomer extends relaxed covenants as weakness persists

(Sharecast News) - Synthomer said on Tuesday that it has secured an extension to its covenant relaxation agreement with its banking syndicate through to the end of 2026, as it navigates weaker-than-expected macroeconomic conditions and ongoing geopolitical uncertainties. The London-listed chemicals group said the amended terms gave it additional headroom, with net debt-to-EBITDA ratio limits raised to 5.25x for December 2025, 4.5x for June 2026 and 4.25x for December 2026.

Those compared with the previous thresholds of 4.75x, 3.5x and 3.25x respectively.

Synthomer said it still expected to remain within the previously agreed 5x covenant for June, but opted to increase it slightly to 5.25x "for prudence".

The company said the move would provide flexibility to manage the business through to an anticipated recovery in earnings over the medium term.

It said it would report its interim results for the six months to the end of June on 5 August.

At 0930 BST, shares in Synthomer were up 3.29% at 113p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.